Autolus’ Chief Scientific Officer, Dr Martin Pulé, to give Keynote Lecture at the EHA-EBMT 2nd European CAR T Cell Meeting...
January 27 2020 - 7:00AM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, announces that the Company’s Founder and Chief
Scientific Officer, Martin Pulé, will be giving the Keynote Lecture
at the upcoming EHA-EBMT 2nd European CAR T Cell Meeting to be held
January 30 to February 1 in Stiges, Spain. The presentation will
include updated clinical data from the ongoing Phase 1/2 clinical
trial of AUTO3 in adult diffuse large B-cell lymphoma (ALEXANDER
Trial), a review of recent data on AUTO1 from the Phase 1 clinical
trial in adult acute lymphoblastic leukemia (ALLCAR19 Trial), as
well as an overview of some of Autolus’ next generation B-cell
malignancy programs.
Keynote Lecture: Improved CAR T
cell approaches for lymphoid malignanciesLocation and
Time: Auditorium, Thursday 30th January 2020, 17:15 PM -
17:45 PM CET
About Autolus Therapeutics
plcAutolus is a clinical-stage biopharmaceutical company
developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and modular
T cell programming technologies, the company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors.
About AUTO1AUTO1 is a CD19 CAR
T cell investigational therapy designed to overcome the limitations
in safety - while maintaining similar levels of efficacy - compared
to current CD19 CAR T cell therapies. Designed to have a fast
target binding off-rate to minimize excessive activation of the
programmed T cells, AUTO1 may reduce toxicity and be less prone to
T cell exhaustion, which could enhance persistence and improve the
T cells' abilities to engage in serial killing of target cancer
cells. AUTO1 is currently being evaluated in two Phase 1 studies,
one in pediatric ALL and one in adult ALL.
About AUTO3AUTO3 is a
programmed T cell therapy containing two independent chimeric
antigen receptors targeting CD19 and CD22 that have each been
independently optimized for single target activity. By
simultaneously targeting two B cell antigens, AUTO3 is designed to
minimize relapse due to single antigen loss in patients with B cell
malignancies. AUTO3 is currently being tested in pediatric ALL in
the AMELIA clinical trial and in diffuse large B cell lymphoma in
the ALEXANDER clinical trial.
Contacts:
Lucinda Crabtree, PhDVice President, Investor
Relations and Corporate Communications+44 (0) 7587 372
619 l.crabtree@autolus.com
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-212-966-3650susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2023 to Apr 2024